BBOT's BBO-10203 Shows Promising Preclinical Results in HER2AMP Models
Event summary
- BBOT presented preclinical data for BBO-10203 at the AACR Annual Meeting 2026, showing it inhibits PI3Kα/AKT signaling in HER2AMP models without causing hyperglycemia.
- BBO-10203 demonstrated strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2AMP models.
- Updated clinical data for BBO-10203 are expected in the second half of 2026.
The big picture
BBOT's presentation at AACR 2026 highlights the potential of BBO-10203 to address a critical interaction in malignant cells, offering a novel approach to cancer treatment. The absence of hyperglycemia and strong combination effects with existing HER2 inhibitors position BBO-10203 as a promising candidate in the oncology market. The upcoming clinical data will be crucial in determining its market potential and competitive positioning.
What we're watching
- Clinical Data
- How the upcoming clinical data in the second half of 2026 will validate the preclinical findings and potential of BBO-10203.
- Combination Therapy
- Whether BBO-10203's combination effects with HER2 inhibitors will position it as a key player in targeted cancer therapies.
- Market Differentiation
- The pace at which BBOT can differentiate BBO-10203 from competing approaches in the RAS and PI3Kα inhibition space.
Related topics